The Week Ahead: Hom...
Health Care: Drugs
Acura Pharmaceuticals Inc. (ACUR: NASDAQ)
$2.35 0.16 | 7.31%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -9.67M | 10.38M | -12.71M | -15.84M |
| Operating Gains/Losses | 8.00K | 8.00K | 14.00K | -3.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 110.00K | -15.00K | 231.00K | 3.17M |
| (Increase) Decrease in Inventories | -219.00K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 941.00K | 53.00K | 0.00 | -382.00K |
| (Decrease) Increase In Other Current Liabilities | -64.00K | -209.00K | -862.00K | -4.19M |
| (Increase) Decrease In Other Working Capital | 6.00K | -466.00K | 0.00 | 0.00 |
| Other Non-Cash Items | 1.73M | 2.46M | 6.75M | 9.20M |
| Net Cash From Continuing Operations | -7.04M | 12.31M | -6.48M | -5.20M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -7.04M | 12.31M | -6.48M | -5.20M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 5.04M |
| Purchases of Property, Plant & Equipment | -147.00K | -131.00K | -41.00K | -220.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -20.13M | -131.00K | -41.00K | 4.82M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 9.00K | 1.29M | 392.00K | 160.00K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -1.05M | -1.83M | 0.00 | 0.00 |
| Net Cash From Financing Activities | -1.04M | -541.00K | 392.00K | 160.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -28.21M | 11.64M | -6.13M | -224.00K |
Portfolios with ACUR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserSUPRATRADE HOT STOCKS (BUY ...
- User©SUPRATRADE HOT STOCKS (...
- User©SUPRATRADE HOT STOCKS (...
Latest ACUR Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 04.18.13 | 02:04 pm
- 5 Stocks Poised for Breakouts 04.05.13 | 02:04 pm
- 4 Stocks Under $5 Moving Higher 10.11.12 | 03:10 pm
- Acura Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript 07.31.12 | 10:07 am
- 8 Stocks Under $10 Moving Higher 03.20.12 | 12:03 pm
- 7 Stocks Under $10 Moving Higher 11.30.11 | 12:11 pm
- Acura Stock Soars (ACUR) 09.30.11 | 02:09 pm
- Acura Stock Soars (ACUR) 08.15.11 | 12:08 pm
- Acura Pharmaceuticals Inc. Stock Upgraded (ACUR) 08.03.11 | 07:08 am
- Pfizer, Pain Therapeutics Drug Rejected by FDA 06.24.11 | 08:06 am
Press Releases for ACUR
- Pfizer And Acura Announce FDA Approval Of Oxectatm (Oxycodone HCL, USP) CII - Business Wire 06.20.11 | 07:06 am
- Kahn Swick & Foti, LLC And Former Louisiana State Attorney General Remind Investors With Large Financial Interests (Over $100,000) Of Important 11/9/2010 Deadline In Securities Class Action Against Acura Pharmaceuticals, Inc. - ACUR - Business Wire 11.03.10 | 05:11 pm
- The Shuman Law Firm Announces The Filing Of A Class Action Lawsuit Against Acura Pharmaceuticals, Inc. - Business Wire 10.21.10 | 02:10 pm
- Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Shareholders Of Acura Pharmaceuticals, Inc. - Business Wire 09.14.10 | 08:09 pm
- Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Acura Pharmaceuticals, Inc. - Business Wire 09.14.10 | 07:09 pm
- The Law Office Of Robbins Umeda LLP Announces The Filing Of A Class Action Suit Against Acura Pharmaceuticals, Inc. - Business Wire 09.14.10 | 06:09 pm
- Law Office Of Jonathan M. Stein, P.L. Investigates Possible Breaches Of Fiduciary Duty By The Officers And Directors Of Acura Pharmaceuticals, Inc. - Business Wire 09.14.10 | 03:09 pm
Partner Headlines for ACUR
- Current Prime Pharma Entries In Anticipation Of Prime Time Exits - Seeking Alpha 11.06.12 | 09:11 am
- Acura Pharmaceuticals Announces Update on AVERSION Products - Benzinga 07.27.12 | 04:07 pm
- Healthcare Business Rewind: Furiex' GOOD NEWS, Pfizer TERMINATES Licenses - Wall St. Cheat Sheet 07.27.12 | 06:07 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Building The Perfect Portfolio: Best Small Cap Stocks - Seeking Alpha 12.02.11 | 08:12 am
- Insider Buys May Send The Wrong Signals - Seeking Alpha 08.22.11 | 09:08 am
- Company News for June 21, 2011 - Corporate Summary - Zacks 06.21.11 | 10:06 am
- Acura Pharmaceuticals: FDA's Drug Decision Friday May Unlock Big Opportunity - Seeking Alpha 06.15.11 | 09:06 am
- 12 Healthcare Companies Looking at June Catalysts - Seeking Alpha 05.30.11 | 04:05 am
- King Pharma Files NDA for Pain Drug - Analyst Blog - Zacks 12.21.10 | 09:12 am
